

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
17 June 2004 (17.06.2004)

PCT

(10) International Publication Number  
**WO 2004/050077 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/202,**  
31/557, A61P 3/02

European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(21) International Application Number:  
PCT/IB2003/005673

(22) International Filing Date: 1 December 2003 (01.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
P-200202963 5 December 2002 (05.12.2002) ES

(71) Applicant (for all designated States except US):  
**PROYECTO EMPRESARIAL BRUDY, S.L.** [ES/ES];  
C. Riera Sant Miquel 3, 2on 4a, E-08006 Barcelona (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DOMINGO PEDRAL, Juan Carlos** [ES/ES]; C. Riera Sant Miquel 3, 2on 4a, E-08006 Barcelona (ES). **DOMINGO PEDRAL, Pere** [ES/ES]; C. Riera Sant Miquel 3, 2on 4a, E-08006 Barcelona (ES).

(74) Agents: **PONTI SALES, Adelaida et al.**; OFICINA PONTI, S.L., C. de Consell de Cent 322, E-08007 Barcelona (ES).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

**Declarations under Rule 4.17:**

- as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF DOCOSAHEXANOIC ACID AS ACTIVE SUBSTANCE FOR THE TREATMENT OF LIPODYSTROPHY

(57) Abstract: Use of an extract of animal, plant or microorganism produced origin comprising docosahexaenoic acid as active substance for the manufacture of a medicament for the treatment of lipodystrophy in a mammal. Said treatment is effective and overcomes the disadvantages of current lipodystrophy treatments in HIV infected patients.

WO 2004/050077 A1

1

USE OF DOCOSAHEXANOIC ACID AS ACTIVE SUBSTANCE FOR THE  
TREATMENT OF LIPODYSTROPHY

5 FIELD OF THE INVENTION

This invention relates to the use of an extract of animal, plant or microorganism-produced origin comprising docosahexaenoic acid as active substance for the  
10 manufacture of a medicament for the treatment of lipodystrophy, particularly in patients infected by the HIV virus.

BACKGROUND OF THE INVENTION

15

Treatments have been available since the end of 1996 which are capable of controlling multiplication of the human immunodeficiency virus (HIV), which is the cause of acquired immune deficiency syndrome (AIDS). These  
20 treatments have been generically so-called highly active anti-retroviral therapy (HAART). The current HAART characteristically consists in the combination of at least three drugs.

There are at present two families of  
25 antiretrovirals that inhibit key enzymes for viral replication and which are the reverse transcriptase inhibitors (nucleoside analogues, nucleotide analogues and nucleoside non-analogues) and the viral protease inhibitors.

30 However, such treatments are not capable of leading to eradication of the virus (elimination thereof) and, to keep the infection controlled they, therefore, have to be administered indefinitely, probably throughout the patient's entire lifetime.

35 Such treatments, of undoubted efficacy in controlling viral replication, are nevertheless not

innocuous for patients, and because the exposure time thereto is, necessarily, very lengthy, their toxic effects tend to accumulate over time.

Since 1997 there began to be detected patients submitted to HAART who presented disorders not previously described in body-fat distribution, accompanied by plasma lipid level disorders.

Briefly, the patients show loss of fat in the face, buttocks, extremities and thorax, accompanied by accumulation of fat inside the abdomen, the back of the neck and in the breast area in women, together with increase plasmatic levels of cholesterol, triglycerides, lowering of HDL cholesterol (protective cholesterol) and increase of LDL cholesterol (harmful cholesterol), insulin resistance (occasionally diabetes) and occasionally arterial hypertension.

This entire set of situations is known as lipodystrophy syndrome.

Approaches to the treatment of lipodystrophy can be summed up in five broad groups:

- (a) Strategies which modify the HAART components, so that this cannot be suppressed without running the risk of losing control over viral replication.
- (b) Drugs (e.g. methformine, rosiglytazone) which cause sensitisation to the action of insulin.
- (c) Drugs which aim to control the lipidic aspects of the syndrome, such as fibrates and statines, which can improve (though rarely normalise) plasmatic lipid disorders.
- (d) Hormone treatments (e.g. growth hormones).
- (e) Facial cosmetic surgery with implants to correct fat loss.

None of the treatments tested so far have shown any efficacy in reversing the disorders in body fat distribution, and the control of lipidic disorders using such measures has been incomplete.

3

It should be mentioned that the foregoing tested pharmacological treatments are not without toxic effects on the patient, which can, occasionally, be serious. They furthermore, mean an additional drug burden, 5 and some of them interact in a potentially serious way with the antiretroviral drugs which HIV-infected patients cannot stop taking.

There is still, therefore, no available treatment for lipodystrophy, in particular in HIV-infected patients, 10 which is effective and does not give rise to the disadvantages of the treatments currently known.

#### **DESCRIPTION OF THE INVENTION**

15 The inventors of the present invention have found a treatment effective against lipodystrophy and which, furthermore, overcomes the disadvantages presented by the current treatments for said illness in HIV-infected patients.

20 This invention relates to the use of an extract of animal, plant or microorganism-produced origin that comprises docosahexaenoic acid as active substance for the manufacture of a medicament for the treatment of lipodystrophy in a mammal.

25 Docosahexaenoic acid (DHA) is an omega-3 fatty acid which contains 22 atoms of carbon, being six of them unsaturated (C22:6 n-3). Such acid is found, mainly, in fish (for example, tuna), microorganisms and plants.

In this invention, "extract of animal, plant or 30 microorganism-produced origin that comprises docosahexaenoic acid as active substance" is taken to mean a composition which includes docosahexaenoic acid, which is obtained from fish, microorganisms and plants, by means of extraction, and optionally, chemical-modification 35 procedures known to those skilled in the art.

In this invention, "microorganism" is taken to mean any microscopic organism, including but not limited to bacteria, protozoa, fungi, viruses and algae, and any of their variants produced by genetic engineering, which are characterized in that they produce DHA.

Docosahexaenoic acid can, thus, be one occurring naturally or one modified chemically. The chemical forms in which the DHA can be found therefore include, but are not restricted to, the free acid of DHA, DHA esters with natural or synthetic alcohols and lipidic forms such as the glycerides, phospholipids, sphingolipids and gangliosides.

In particular, this invention relates to the use of an extract of animal, plant or microorganism-produced origin that comprises docosahexaenoic acid as active substance for the manufacture of a medicament for the treatment of lipodystrophy in mammals, said extract having a DHA content that ranges between 5% and 100% (w/w), preferably between 50% and 100% (w/w).

Surprisingly, the inventors of the present invention have found that the fact that the DHA is a physiological substance possessing multiple actions on the adipocytes (fat cells) and on plasma lipid levels permits the effective treatment of lipodystrophy.

Principal among these is its ability to promote differentiation (multiplication) of the adipocytes, reduce blood triglyceride and cholesterol levels, increase HDL cholesterol level, reduce LDL cholesterol level, and reduce arterial blood pressure.

Additionally, the DHA possesses anti-inflammatory properties (it inhibits the secretion of alpha tumour necrosis factor) which, as will be shown below, is high in patients with lipodystrophy.

In a second aspect, a dosage of the medicament of the invention is administered equal to or higher than 100 mg/day, a dosage of 4 grams per day being preferable.

## 5

A medicament according to this invention can be administered orally or parenterally.

Depending on the chosen route of administration, pharmaceutically acceptable diluents, excipients and/or 5 carriers of the active substance can be included, such as liposomes, microemulsions, micelles, etc.

In a third aspect, the medicament of the invention is administered to a human, preferably an HIV-infected human.

10 It has been found, indeed, that administration of the medicament of the invention in cultured adipocytes is capable of inhibiting the toxic effects caused by the exposure of these cells to the antiretroviral drugs.

Therefore, and taking into account the beneficial 15 effects pointed out above, the medicament of this invention can perform a beneficial action on lipodystrophy syndrome, especially in HIV-infected patients treated under HAART regimens, having the following advantageous aspects in relation to current treatments:

- 20 1. adipocytary differentiation promoter activity;  
2. hypolipemiant activity;  
3. anti-inflammatory activity (reduction of the alpha tumour necrosis factor);  
4. antihypertensive activity;  
25 5. absence of side effects at the dosages administered;  
6. absence of interactions with the antiretroviral regimen components due to it being a medicament that is not metabolised by routes common to those of the 30 antiretroviral drugs (it should be remembered that the patient cannot dispense with HAART).

There follows, by way of non-restrictive illustration, an example of embodiment of this invention.

EXAMPLES*Example 1*

5           Four HIV-infected patients under HAART regimen and  
presenting lipodystrophy syndrome were administered 4  
grams/day of a tuna oil with a DHA content of 70%. After  
three months' administration of DHA to said patients, the  
following discoveries were made, even taking account of  
10 the short period of administration:

1. Partial reversal of body-fat distribution disorders, with
  - 1.1 improvement in facial fat loss;
  - 15       1.2 improvement in fat loss in buttocks and extremities;
  - 1.3 no increase in intra-abdominal fat.
2. Mean reduction of 56% in the plasma triglycerides number.
- 20       3. Mean reduction of 25% in the total plasma cholesterol number.
4. Mean increase of 9% in the plasma HDL cholesterol number.
5. Mean reduction of 18% in the plasma LDL  
25       cholesterol number.

These results, shown in the table on the following page, allow us to conclude that the administration of DHA at dosages of 4 grams a day over the course of 3 months is  
30 capable of improving lipodystrophy and the lipidic disorders associated with it.

Table

	before the treatment					after 3 months of treatment				
	VLDL	COL.	TG	HDL	LDL	VLDL	COL.	TG	HDL	LDL
Patient 1	1.27	6.8	7.1	1.1	3.67	0.46	5.46	1	1.57	3.43
Patient 2	3.96	9.95	8.62	1.12	4.87	3.74	9.48	10.66	0.91	3.35
Patient 3	2.18	5.18	6.29	1.09	1.91	0.8	3.82	1.73	1.05	1.97
Patient 4	11.41	19.13	30.8	1.92	0.79	1.82	9.9	3.41	0.98	6.67



**Example 2**

From the four patients treated with DHA at elevated dosages (1,5 g/day), all of them have been monitored for 5 300 days and, although notable fluctuations are observed, especially regarding to the triglycerids (see Table 2), after 300 days of monitoring, the reduction's mean in the number of triglycerids with respect to the basal level is 66% and for the cholesterol is 28,0%. At the same time, 10 the HDL cholesterol shows a drop op 11,6%.

All patients have improved their fat redistribution, from the point of view subjective and according to the skill's criterion.

TABLE 2

Patient	before the treatment					15 days of treatment					30 days of treatment				
	COL.	TG	HDL	LDL	VLDL	COL.	TG	HDL	LDL	VLDL	COL.	TG	HDL	LDL	VLDL
1	6.8	7	1.1	3.67	1.27	6.37	1.16	1.7	4.14	0.53	6.16	1.35	1.79	3.7	0.62
2	9.95	8.6	1.12	4.87	3.96	9.74	5.98	0.98	6.07	2.61	8.4	6.9	0.86	4.3	3.18
3	5.18	6.2	1.09	1.91	2.18	3.92	3.11	1.05	1.86	1.01	4.07	3.09	1.06	2.0	0.97
4	19.13	30	1.92	0.79	11.41	8.73	5.18	1.03	5.35	2.35	8.5	5.74	1.16	5.0	2.26
Patient	60 days of treatment					120 days of treatment					180 days of treatment				
	COL.	TG	HDL	LDL	VLDL	COL.	TG	HDL	LDL	VLDL	COL.	TG	HDL	LDL	VLDL
1	5.46	1	1.57	3.43	0.46	5.49	1.45	1.56	3.26	0.67	6.15	2.63	1.56	3.38	1.21
2	9.48	10.66	0.91	3.35	3.74	8.24	6.36	1.08	4.6	2.56	9.64	15.75	1.04	2.3	4.38
3	3.82	1.73	1.05	1.97	0.8	3.47	1.51	1.16	1.61	0.7	3.76	2.87	0.94	1.5	132
4	9.9	3.41	0.98	6.67	1.82	13.63	31.7	0.7	1.46	9.67	13.21	16.37	1.48	2.09	3.97
Patient	240 days of treatment					300 days of treatment					360 days of treatment				
	COL.	TG	HDL	LDL	VLDL	COL.	TG	HDL	LDL	VLDL	COL.	TG	HDL	LDL	VLDL
1	5.7	1.59	1.67	3.3	0.73	6.01	1.57	1.23	4.06	0.72					
2	8.1	5.36	0.98	4.93	2.12	9.3	7.21	1.08	5.31	2.92					
3	4.04	1.85	1.09	2.1	0.85	4.34	1.62	0.89	2.7	0.75					
4	5.33	2.18	1.17	3.16	1	4.27	1.36	1.22	2.42	0.63					

**CLAIMS**

1. Use of an extract of animal, plant or  
5 microorganism-produced origin that comprises  
docosahexaenoic acid as active substance for the  
manufacture of a medicament for the treatment of  
lipodystrophy in a mammal.

2. Use according to Claim 1, characterised in that  
10 the amount of docosahexaenoic acid in said extract is  
higher than or equal to 100 mg/day.

3. Use according to Claim 2, characterised in that  
said amount of docosahexaenoic acid in said extract is 4  
grams/day.

15 4. Use according to any of claims 1 to 3, in which  
the medicament promotes adipocytary differentiation.

5. Use according to any of claims 1 to 3, in which  
the medicament has hypolipemiant activity.

6. Use according to any of claims 1 to 3, in which  
20 the medicament reduces the alpha tumour necrosis factor.

7. Use according to any of claims 1 to 3, in which  
the medicament has antihypertensive activity.

8. Use according to claim 1, in which the  
medicament is capable of inhibiting the toxic effects  
25 caused by the administration of an antiretroviral drug.

9. Use according to Claim 1, in which said  
docosahexaenoic acid is present in said extract in a  
concentration which ranges between 5% and 100% (w/w).

10. Use according to Claim 9, in which said  
30 docosahexaenoic acid is present in said extract in a  
concentration which ranges between 50% and 100% (w/w).

11. Use according to any of the preceding claims,  
in which the medicament is administered orally.

12. Use according to any of the preceding claims,  
35 in which the drug is administered parenterally.

11

13. Use according to Claim 1, in which said mammal is a human.

14. Use according to Claim 13, in which said human is infected with the HIV virus.

5